

# Stefano A Pileri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1452647/publications.pdf>

Version: 2024-02-01

132  
papers

15,189  
citations

66234

42  
h-index

18606

119  
g-index

137  
all docs

137  
docs citations

137  
times ranked

15558  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood</i> , 2016, 127, 2375-2390.   | 0.6 | 5,965     |
| 2  | The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. <i>Blood</i> , 2011, 117, 5019-5032.  | 0.6 | 1,681     |
| 3  | The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.  | 0.6 | 512       |
| 4  | Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. <i>Blood</i> , 2014, 123, 2915-2923.  | 0.6 | 435       |
| 5  | A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. <i>Blood</i> , 2000, 95, 2084-2092.  | 0.6 | 409       |
| 6  | Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015, 27, 516-532.   | 7.7 | 378       |
| 7  | Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. <i>Blood</i> , 2011, 117, 3402-3408.  | 0.6 | 376       |
| 8  | Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score. <i>Journal of Clinical Oncology</i> , 2006, 24, 2472-2479.  | 0.8 | 354       |
| 9  | A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2014, 123, 1293-1296.   | 0.6 | 345       |
| 10 | Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. <i>Blood</i> , 2007, 110, 2316-2323. | 0.6 | 293       |
| 11 | Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project. <i>Journal of Clinical Oncology</i> , 2013, 31, 240-246.   | 0.8 | 287       |
| 12 | Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. <i>Journal of Clinical Investigation</i> , 2007, 117, 823-834.  | 3.9 | 272       |
| 13 | Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. <i>Haematologica</i> , 2013, 98, 239-246.  | 1.7 | 268       |
| 14 | Novel markers of normal and neoplastic human plasmacytoid dendritic cells. <i>Blood</i> , 2008, 111, 3778-3792.   | 0.6 | 204       |
| 15 | Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. <i>Blood</i> , 2019, 133, 1664-1676.  | 0.6 | 184       |
| 16 | Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3019-3025.                            | 0.8 | 129       |
| 17 | Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma. <i>PLoS Pathogens</i> , 2015, 11, e1005158.   | 2.1 | 127       |
| 18 | Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. <i>Blood</i> , 2015, 125, 2530-2543.   | 0.6 | 125       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Reproducing the molecular subclassification of peripheral T-cell lymphomaâ€“NOS by immunohistochemistry. <i>Blood</i> , 2019, 134, 2159-2170.   | 0.6  | 120       |
| 20 | CD30 expression in peripheral T-cell lymphomas. <i>Haematologica</i> , 2013, 98, e81-e82.   | 1.7  | 117       |
| 21 | PDGFR blockade is a rational and effective therapy for NPM-ALKâ€“driven lymphomas. <i>Nature Medicine</i> , 2012, 18, 1699-1704.  | 15.2 | 113       |
| 22 | Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology</i> , the, 2017, 4, e15-e23.  | 2.2  | 106       |
| 23 | Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 764-769.  | 3.3  | 100       |
| 24 | Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2017, 18, 1076-1088. | 5.1  | 100       |
| 25 | The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. <i>Haematologica</i> , 2010, 95, 432-439.   | 1.7  | 99        |
| 26 | Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. <i>Annals of Oncology</i> , 2018, 29, 2363-2370.   | 0.6  | 89        |
| 27 | Cytotoxic T-cell and NK-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2014, 38, e60-e71.  | 2.1  | 83        |
| 28 | Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects. <i>Cancers</i> , 2019, 11, 595.   | 1.7  | 70        |
| 29 | Expression of CD52 in peripheral T-cell lymphoma. <i>Haematologica</i> , 2007, 92, 566-567.   | 1.7  | 67        |
| 30 | Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2016, 34, 4015-4022.  | 0.8  | 66        |
| 31 | The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology</i> , the, 2016, 3, e467-e479.  | 2.2  | 63        |
| 32 | Breast implant-associated anaplastic large cell lymphoma: A comprehensive review. <i>Cancer Treatment Reviews</i> , 2020, 84, 101963.   | 3.4  | 61        |
| 33 | Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. <i>Blood</i> , 2020, 135, 534-541.  | 0.6  | 61        |
| 34 | Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 467-489.   | 1.4  | 59        |
| 35 | Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. <i>Haematologica</i> , 2019, 104, 729-737.  | 1.7  | 58        |
| 36 | Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 6553-6569.  | 0.8  | 58        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. <i>Blood</i> , 2021, 138, 213-220.   | 0.6 | 53        |
| 38 | Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennert's personal archive. <i>Histopathology</i> , 2011, 59, 679-691.  | 1.6 | 51        |
| 39 | The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 215-226.                            | 1.2 | 51        |
| 40 | Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. <i>British Journal of Haematology</i> , 2018, 181, 760-769.                            | 1.2 | 49        |
| 41 | Revising the historical collection of epithelioid cell-rich lymphomas of the Kiel Lymph Node Registry: what is Lennert's lymphoma nowadays?. <i>Histopathology</i> , 2011, 59, 1173-1182.  | 1.6 | 47        |
| 42 | Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. <i>Oncotarget</i> , 2017, 8, 111836-111846.                                   | 0.8 | 44        |
| 43 | Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. <i>Haematologica</i> , 2005, 90, 341-7. | 1.7 | 43        |
| 44 | Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. <i>Modern Pathology</i> , 2020, 33, 179-187.                                      | 2.9 | 37        |
| 45 | Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. <i>Blood Advances</i> , 2020, 4, 4124-4135.  | 2.5 | 37        |
| 46 | New molecular insights into peripheral T cell lymphomas. <i>Journal of Clinical Investigation</i> , 2012, 122, 3448-3455.  | 3.9 | 35        |
| 47 | CD38, BCL-2, PD-1, and PD-L1 expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?. <i>American Journal of Hematology</i> , 2017, 92, E1-E2.   | 2.0 | 33        |
| 48 | Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas. <i>Oncotarget</i> , 2016, 7, 224-240.   | 0.8 | 33        |
| 49 | Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody. <i>Histopathology</i> , 2012, 61, 33-46.                         | 1.6 | 32        |
| 50 | Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 214-227.                               | 2.0 | 31        |
| 51 | slan+ Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP. <i>Cancer Research</i> , 2018, 78, 3544-3559.  | 0.4 | 31        |
| 52 | Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. <i>Oncotarget</i> , 2015, 6, 6544-6552.  | 0.8 | 31        |
| 53 | Follicular helper T-cell-related lymphomas. <i>Blood</i> , 2015, 126, 1733-1734.   | 0.6 | 29        |
| 54 | Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 228-240.                                | 2.0 | 29        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2014, 27, 1345-1354.   | 2.9 | 28        |
| 56 | In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 125.  | 6.9 | 28        |
| 57 | The clinicopathologic spectrum of mature aggressive B cell lymphomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 453-466.  | 1.4 | 27        |
| 58 | A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas. <i>IScience</i> , 2020, 23, 101562.  | 1.9 | 27        |
| 59 | Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation. <i>BMC Cancer</i> , 2015, 15, 668.  | 1.1 | 26        |
| 60 | Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas. <i>Human Pathology</i> , 2019, 90, 60-69.   | 1.1 | 25        |
| 61 | Novel markers in pediatric-type follicular lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 771-779.   | 1.4 | 22        |
| 62 | Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. <i>World Journal of Gastroenterology</i> , 2014, 20, 7049.  | 1.4 | 22        |
| 63 | CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1. <i>Experimental Hematology</i> , 2015, 43, 268-276.e5.   | 0.2 | 21        |
| 64 | Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 657-664.  | 2.1 | 21        |
| 65 | Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 575-582. | 1.4 | 20        |
| 66 | DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS. <i>Blood</i> , 2022, 140, 1278-1290.  | 0.6 | 20        |
| 67 | Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6039-6053.  | 3.2 | 17        |
| 68 | Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. <i>Journal of Clinical Oncology</i> , 2022, 40, 4261-4275.  | 0.8 | 17        |
| 69 | miRNA expression profiling divides follicular dendritic cell sarcomas into two groups, related to fibroblasts and myopericytomas or Castlemans disease. <i>European Journal of Cancer</i> , 2016, 64, 159-166.   | 1.3 | 16        |
| 70 | Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 259-267.                                   | 1.4 | 15        |
| 71 | Pathology of nodal marginal zone lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 50-55.   | 0.7 | 14        |
| 72 | EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 2). <i>Cancers</i> , 2021, 13, 4527.  | 1.7 | 14        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Deregulation of miRNAs-cMYC circuits is a key event in refractory celiac disease type-2 lymphomagenesis. <i>Clinical Science</i> , 2020, 134, 1151-1166.   | 1.8 | 14        |
| 74 | PATHOBIOLOGY OF HODGKIN LYMPHOMA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014040.  | 0.5 | 13        |
| 75 | Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T-Cell lymphoma. <i>Cell Reports</i> , 2022, 39, 110695.  | 2.9 | 13        |
| 76 | Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 511-521.   | 0.9 | 12        |
| 77 | Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-Cell lymphoma. <i>Cancer</i> , 2022, 128, 1004-1014.   | 2.0 | 12        |
| 78 | Immunohistochemistry of Bone-Marrow Biopsy. <i>Leukemia and Lymphoma</i> , 1997, 26, 69-75.  | 0.6 | 11        |
| 79 | Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018, 59, 2904-2910. | 0.6 | 11        |
| 80 | Pathobiology of ALK-negative anaplastic large cell lymphoma. <i>Mental Illness</i> , 2011, 3, 5.   | 0.8 | 10        |
| 81 | Prospective subgroup analyses of the randomized MCL (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 224-235.                    | 1.2 | 10        |
| 82 | Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 330-334.   | 1.2 | 10        |
| 83 | Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas. <i>Cells</i> , 2021, 10, 675.   | 1.8 | 10        |
| 84 | Peripheral T-Cell Lymphoma, Not Otherwise Specified: Clinical Manifestations, Diagnosis, and Future Treatment. <i>Cancers</i> , 2021, 13, 4535.  | 1.7 | 9         |
| 85 | Reproducibility of SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients. <i>Human Pathology</i> , 2017, 59, 94-101.   | 1.1 | 8         |
| 86 | A three-gene signature based on MYC, BCL-2, and NFKBIA improves risk stratification in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2405-2416.   | 1.7 | 8         |
| 87 | Evolutionary crossroads: morphological heterogeneity reflects divergent intra-clonal evolution in a case of high-grade B-cell lymphoma. <i>Haematologica</i> , 2020, 105, e432-e436.   | 1.7 | 8         |
| 88 | BRAF <sup>V600E</sup> mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients. <i>British Journal of Haematology</i> , 2015, 170, 282-285.  | 1.2 | 7         |
| 89 | Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients. <i>European Journal of Cancer</i> , 2021, 148, 277-286.   | 1.3 | 7         |
| 90 | T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker. <i>Cancers</i> , 2021, 13, 3102.                                  | 1.7 | 7         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Histopathology of B-cell chronic lymphocytic leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 807-826.   | 0.9 | 6         |
| 92  | Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 749-757.   | 1.4 | 6         |
| 93  | Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2021, 13, 4680.   | 1.7 | 6         |
| 94  | Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial. <i>Blood</i> , 2018, 132, 1627-1627.  | 0.6 | 6         |
| 95  | Intrafollicular Epstein-Barr virus-positive large B cell lymphoma. A variant of "germinotropic" lymphoproliferative disorder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 441-450.   | 1.4 | 5         |
| 96  | B-cell lymphomas with discordance between pathological features and clinical behavior. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 439-451.  | 1.4 | 5         |
| 97  | HHV8-Negative Effusion-Based Large B Cell Lymphoma Arising in Chronic Myeloid Leukemia Patients under Dasatinib Treatment: A Report of Two Cases. <i>Biology</i> , 2021, 10, 152.   | 1.3 | 5         |
| 98  | Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making. <i>Blood</i> , 2019, 134, 661-661. | 0.6 | 5         |
| 99  | Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. <i>Experimental Hematology and Oncology</i> , 2015, 4, 24.   | 2.0 | 4         |
| 100 | Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network. <i>Leukemia and Lymphoma</i> , 2016, 57, 400-410.   | 0.6 | 4         |
| 101 | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis. <i>Diagnostics</i> , 2021, 11, 1150.   | 1.3 | 4         |
| 102 | Cell-of-Origin Identification and Prognostic Correlation in HIV-Associated Diffuse Large B-Cell Lymphomas: Results of an Italian Multicentric Study. <i>Blood</i> , 2018, 132, 5294-5294.   | 0.6 | 4         |
| 103 | The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade. <i>Blood Advances</i> , 2022, 6, 4634-4644.   | 2.5 | 4         |
| 104 | Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. <i>Blood</i> , 2018, 132, 789-789.  | 0.6 | 3         |
| 105 | Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi. <i>Blood</i> , 2018, 132, 2902-2902.  | 0.6 | 3         |
| 106 | EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 3). <i>Cancers</i> , 2021, 13, 6021.   | 1.7 | 3         |
| 107 | Primary Diffuse Large B-Cell Lymphoma of the Urinary Bladder: Update on a Rare Disease and Potential Diagnostic Pitfalls. <i>Current Oncology</i> , 2022, 29, 956-968.  | 0.9 | 3         |
| 108 | Understanding lymphoma molecular complexity. <i>Blood</i> , 2017, 130, 1780-1781.   | 0.6 | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | The Pathobiology and Treatment of Hodgkin Lymphoma. Where do We go from Gianni Bonadonna's Lesson?. <i>Tumori</i> , 2017, 103, 101-113.  | 0.6 | 2         |
| 110 | Plasmablastic lymphoma: one or more tumors?. <i>Haematologica</i> , 2021, 106, 2542-2543.  | 1.7 | 2         |
| 111 | Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi. <i>Blood</i> , 2016, 128, 472-472.   | 0.6 | 2         |
| 112 | Dissecting diffuse large B-cell lymphomas of the "not otherwise specified" type: the impact of molecular techniques. <i>F1000Research</i> , 2018, 7, 1966.   | 0.8 | 2         |
| 113 | Potential Pathogenetic Role of <i>Achromobacter</i> ( <i>Alcaligenes</i> ) <i>Xylosoxidans</i> in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG. <i>Blood</i> , 2011, 118, 880-880.          | 0.6 | 2         |
| 114 | Prognostic Factors and Survival in Non-Hodgkin's Lymphomas: The Experience of the Istituto Oncologico Romagnolo (IOR). <i>Leukemia and Lymphoma</i> , 1994, 14, 475-482.   | 0.6 | 1         |
| 115 | Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study. <i>Blood</i> , 2018, 132, 4078-4078.                          | 0.6 | 1         |
| 116 | Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies. <i>Blood</i> , 2018, 132, 676-676. | 0.6 | 1         |
| 117 | Arginase 1 Is a Marker of Myeloid-Mediated Immunosuppression with Prognostic Meaning in Classic Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1770-1770.   | 0.6 | 1         |
| 118 | Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. <i>Blood</i> , 2016, 128, 4096-4096.  | 0.6 | 1         |
| 119 | Identification of Differentially Expressed miRNAs in Peripheral t-Cell Lymphomas. <i>Blood</i> , 2011, 118, 773-773.   | 0.6 | 1         |
| 120 | VAV1 Activating Mutations and Translocations in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2741-2741.  | 0.6 | 1         |
| 121 | A multicenter, open label, uncontrolled, phase II clinical trial evaluating the safety and efficacy of venetoclax in combination with atezolizumab and obinutuzumab in richter transformation of CLL. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS7575-TPS7575.                     | 0.8 | 1         |
| 122 | SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validity"reply. <i>Human Pathology</i> , 2017, 66, 238-239.   | 1.1 | 0         |
| 123 | Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma "Authors' reply. <i>Lancet Haematology</i> , 2017, 4, e64-e66.  | 2.2 | 0         |
| 124 | Cytotoxic Epstein-Barr virus-positive large B cell lymphoma: a regulatory B cell-derived neoplasia?. <i>Histopathology</i> , 2017, 70, 650-656.  | 1.6 | 0         |
| 125 | Primary Bone Lymphoma of the Talus: A Challenging Diagnosis. <i>Tumori</i> , 2017, 103, S62-S65.   | 0.6 | 0         |
| 126 | Diffuse large B-cell lymphoma: the stuff of cell-of-origin and microenvironment. <i>Oncotarget</i> , 2019, 10, 3991-3993.  | 0.8 | 0         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Lymphoma Occurring during Pregnancy: Obstetric Outcome and Overall Survival in a Series of 19 Patients. <i>Blood</i> , 2019, 134, 5289-5289.   | 0.6 | 0         |
| 128 | B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in 18 Consecutive Patients from Two Italian Institutions. <i>Blood</i> , 2019, 134, 1631-1631.   | 0.6 | 0         |
| 129 | Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO). <i>Blood</i> , 2019, 134, 5283-5283.  | 0.6 | 0         |
| 130 | The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi. <i>Blood</i> , 2019, 134, 2025-2025. | 0.6 | 0         |
| 131 | The development of more than one histologic type of lymphoma in the same patient is frequent and confers a worse prognosis. <i>Haematologica</i> , 2005, 90, 293.  | 1.7 | 0         |
| 132 | Abstract 3279: Dual inhibition of EZH2 and histone deacetylases for the treatment of lymphomas with epigenetic aberrations. <i>Cancer Research</i> , 2022, 82, 3279-3279.  | 0.4 | 0         |